For example, Cloughesy et al., found that neoadjuvant programmed cell death 1 (PDCD1) immunotherapy combined with postoperative adjuvant therapy significantly prolonged OS in glioma patients. This evidence concerns the gene PDCD1 and central nervous system cancer.